M. Kathryn Liszewski, V. Bala Subramanian, John P. Atkinson
{"title":"补体抑制剂作为治疗剂","authors":"M. Kathryn Liszewski, V. Bala Subramanian, John P. Atkinson","doi":"10.1016/S0197-1859(00)80025-4","DOIUrl":null,"url":null,"abstract":"<div><p>This report has described several currently evolving strategies and therapeutic agents designed to inhibit the complement system. Many others can be envisioned. Analagous to the utility of therapeutic agents that inhibit the coagulation cascade, it can be anticipated that complement inhibitors will find an important niche in our armamentarium of drugs to reduce undesirable inflammatory reactions</p></div>","PeriodicalId":100270,"journal":{"name":"Clinical Immunology Newsletter","volume":"17 12","pages":"Pages 168-173"},"PeriodicalIF":0.0000,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-1859(00)80025-4","citationCount":"4","resultStr":"{\"title\":\"Complement inhibitors as therapeutic agents\",\"authors\":\"M. Kathryn Liszewski, V. Bala Subramanian, John P. Atkinson\",\"doi\":\"10.1016/S0197-1859(00)80025-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This report has described several currently evolving strategies and therapeutic agents designed to inhibit the complement system. Many others can be envisioned. Analagous to the utility of therapeutic agents that inhibit the coagulation cascade, it can be anticipated that complement inhibitors will find an important niche in our armamentarium of drugs to reduce undesirable inflammatory reactions</p></div>\",\"PeriodicalId\":100270,\"journal\":{\"name\":\"Clinical Immunology Newsletter\",\"volume\":\"17 12\",\"pages\":\"Pages 168-173\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0197-1859(00)80025-4\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Immunology Newsletter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0197185900800254\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Newsletter","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0197185900800254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
This report has described several currently evolving strategies and therapeutic agents designed to inhibit the complement system. Many others can be envisioned. Analagous to the utility of therapeutic agents that inhibit the coagulation cascade, it can be anticipated that complement inhibitors will find an important niche in our armamentarium of drugs to reduce undesirable inflammatory reactions
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
